Determination of P-glycoprotein inhibition by excipients and their combinations using an integrated high-throughput process

Journal of Pharmaceutical Sciences

Volumn 93, Issue 11, 2004, Pages 2755-2767

  Wang, Szu Wen ^a   Monagle, Julie ^b   McNulty, Chris ^b   Putnam, David ^c   Chen, Hongming ^b  

^a University of California at Irvine   (United States)

^b TransForm Pharmaceuticals Inc   (United States)

^c Department of Obstetrics Gynecology   (United States)

Author keywords

Combinatorial chemistry; Efflux pumps; Excipients; Formulation; High throughput technologies; P glycoprotein; Pegylation

Indexed keywords

CREMOPHOR; CYCLOSPORIN A; DIETHYLENE GLYCOL MONOETHYL ETHER; EXCIPIENT; FATTY ACID ESTER; GELUCIRE; GLYCOPROTEIN P; LABRASOL; MACROGOL 10000; MACROGOL 200; MACROGOL 6000; MACROGOL DERIVATIVE; MACROGOL STEARATE; NONOXINOL; NONOXINOL 9; OCTOXINOL; POLIDOCANOL; POLOXAMER; POLYETHYLENEGLYCOL FATTY ACID ESTER; POLYETHYLENEGLYCOL GLYCERYL FATTY ACID; POLYOXYETHYLENE OLEYL ETHER; POLYSORBATE; POLYSORBATE 20; POLYSORBATE 40; POLYSORBATE 60; POLYSORBATE 80; TRITON X 100; TYLOXAPOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ASSAY; AUTOMATION; CELL GROWTH; CELL LINE; CELL STRAIN 3T3; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; COMBINATORIAL CHEMISTRY; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG FORMULATION; HIGH THROUGHPUT PROCESS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; SCREENING TEST;

EID: 8644277940     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20183     Document Type: Article

References (27)

1. Orlowski S, Garrigos M. 1999. Multiple recognition of various amphiphilic molecules by the multidrug resistance P-glycoprotein: Molecular mechanisms and pharmacological consequences coming from functional interactions between various drugs. Anticancer Res 19:3109-3124.
2. Fromm MF. 2000. P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 38(2): 69-74.
3. Hunter J, Hirst BH. 1997. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug adsorption. Adv Drug Delivery Rev 25:129-157.
4. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. 1997. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 40(Suppl):S13-S19.
5. Asperen JV, Tellingen OV, Beijnen JH. 1998. The pharmacological role of P-glycoprotein in the intestinal epithelium. Pharmacol Res 37(6):429-435.
6. Terwogt JMM, Malingre MM, Beijnen JH, Huinink WWTB, Rosing H, Koopman FJ, Telligen OV, Swart M, Schellens JHM. 1999. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 5:3379-3384.
7. Malingre MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM, Huinink WWTB, Schellens JHM. 2001. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 84(1): 42-47.
8. Seebulluck F, Ashford MB, O'Driscoll CM. 2003. The effects of Pluronic Block copolymers and Cremophor EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells. Pharm Res 20(7):1085-1092.
9. Dintaman JM, Silverman JA. 1999. Inhibition of P-glycoprotein by D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 16:1550-1556.
10. Komarov PG, Shtil AA, Buckingham LE, Balasubramanian M, Piraner O, Emanuele RM, Roninson IB, Coon JS. 1996. Inhibition of cytarabine-induced MDR1 (P-glycoprotein) gene activation in human tumor cells by fatty acid-polyethylene glycol-fatty acid diesters, novel inhibitors of P-glycoprotein function. Int J Cancer 68(2):245-250.
11. Hugger ED, Cole CJ, Raub TJ, Burton PS, Borchardt RT. 2003. Automated analysis of polyethylene glycol-induced inhibition of P-glycoprotein activity in vitro. J Pharm Sci 91(1):21-26.
12. Santoni-Rugiu E, Silverman JA. 1997. Functional characterization of the rat mdr1b encoded P-glycoprotein: Not all inducing agents are substrates. Carcinogenesis 18:2255-2263.
13. Nerurkar MM, Burton PS, Borchardt RT. 1996. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm Res 13: 528-534.
14. Handbook of pharmaceutical additives. 1st ed. 1995. Edicott, New York: Synapse Information Resources, Inc.
15. Handbook of pharmaceutical excipients. 3rd ed. 2000. Washington DC: American Pharmaceutical Association.
16. Inactive ingredient guide. 1996. FDA, Center for Drug Evaluation and Research.
17. Hansen MB, Nielsen SE, Berg K. 1989. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119:203-210.
18. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxic assays. J Immunol Methods 65:55-63.
19. Sparreboom A, Asperen JV, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH, Tellingen OV. 1997. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035.
20. Kabanov AV, Alakhov V, Chekhonin VP, Batrakova EV, Kabanov VA. 2000. Use of poloxamers as P-gp inhibitors. US patent 6153193.
21. Aungst BJ, Nguyen NH, Rogers NJ, Rowe SM, Hussain MA, White SJ, Shum L. 1997. Amphiphilic vehicles improve the oral bioavailability of a poorly soluble HIV protease inhibitor at high doses. Int J Pharm 156:79-88.
22. Barker SA, Yap SP, Yuen KH, McCoy CP, Murphy JR, Craig DQM. 2003. An investigation into the structure and bioavailability of alpha-tocopherol dispersions in Gelucire 44/14. J Controlled Release 91:477-488.
23. Mehta SC. 1998. Issues and approaches for improving the solubility and bioavailability of poorly water soluble compounds. Bull Tech Gattefosse 91:65-71.
24. Buckingham LE, Balasubramanian M, Emanuele RM, Clodfelter KE, Coon JS. 1995. Comparison of Solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agents. Int J Cancer 62:436-442.
25. Kessel D, Woodburn K, Decker D, Sykes E. 1995. Fractionation of Cremophor EL delineates components responsible for plasma lipoprotein alterations and multidrug resistance reversal. Oncol Res 7:207-212.
26. Lo Y-L. 2003. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J Controlled Release 90:37-48.
27. Rege BD, Kao JPY, Polli JE. 2002. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 16:237-246.